4SC AG could earn up to €96 million (US$125 million) in option and milestone payments arising out of a preclinical drug development deal in inflammatory skin disease with Leo Pharma A/S, as well as double-digit royalties on eventual product sales. Read More
Small biotech Psyadon Pharmaceuticals made a big clinical move by initiating a Phase III study of ecopipam – its only asset – for the treatment of self-injurious behaviors in the ultra-rare orphan disease Lesch-Nyhan disorder. Read More
Brickell Biotech Inc., of Miami, landed a $7 million Series B financing with a new partner, Amorepacific Ventures, which is affiliated with Amorepacific Group, a large Korean aesthetics company. Read More
LONDON – Identification of a protein that orchestrates many of the changes that permit a normal cell to turn into a cancer cell will open up an entirely new field of cancer therapeutics, the researchers who made the discovery predicted. Read More
LONDON – Start-up BioMoti Ltd. secured its first private financing in a seed round of £150,000 (US$227,000) to advance its Oncojan platform technology, a microparticle carrier system combining targeted delivery of chemotherapy drugs with their controlled release within tumor cells. Read More
• CytoDyn Inc., of Portland, Ore., said it entered a research collaboration with the Scripps Research Institute to study the firm's humanized anti-CCR5 antibody, PRO 140, in a pre-exposure prophylaxis model of HIV infection. Read More
• Integrated BioTherapeutics Inc., of Gaithersburg, Md., said it started a Phase I trial testing the safety and immunogenicity of its staphylococcal enterotoxin B vaccine, STEBVax, in healthy adults. Read More
• United Therapeutics Corp., of Silver Spring, Md., reported total revenues of $243.8 million for the fourth quarter, with net income totaling $83.3 million, or $1.65 per share. Those figures were well above consensus estimates, which had predicted $233 million in revenue and earnings per share of $1.25. Read More
• Shionogi & Co. Ltd., of Osaka, Japan, said the FDA approved Osphena (ospemifene) to treat women experiencing moderate to severe dyspareunia. Read More
